Israel Cannabis Pharmaceuticals Market Size & Outlook
Israel cannabis pharmaceuticals market, 2018-2030 (US$M)
Related Markets
Israel cannabis pharmaceuticals market highlights
- The Israel cannabis pharmaceuticals market generated a revenue of USD 37.7 million in 2023 and is expected to reach USD 931.4 million by 2030.
- The Israel market is expected to grow at a CAGR of 58.1% from 2024 to 2030.
- In terms of segment, epidiolex was the largest revenue generating brand type in 2023.
- Other Brands is the most lucrative brand type segment registering the fastest growth during the forecast period.
Cannabis pharmaceuticals market data book summary
| Market revenue in 2023 | USD 37.7 million |
| Market revenue in 2030 | USD 931.4 million |
| Growth rate | 58.1% (CAGR from 2023 to 2030) |
| Largest segment | Epidiolex |
| Fastest growing segment | Other Brands |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Sativex, Epidiolex, Other Brands |
| Key market players worldwide | Jazz Pharmaceuticals PLC, AbbVie Inc, Insys Therapeutics, Bausch Health Companies Inc |
Other key industry trends
- In terms of revenue, Israel accounted for 1.1% of the global cannabis pharmaceuticals market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Israel cannabis pharmaceuticals market is projected to lead the regional market in terms of revenue in 2030.
- Israel is the fastest growing regional market in Middle East & Africa and is projected to reach USD 931.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cannabis Pharmaceuticals Market Scope
Cannabis Pharmaceuticals Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Israel cannabis pharmaceuticals market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cannabis pharmaceuticals market will help companies and investors design strategic landscapes.
Epidiolex was the largest segment with a revenue share of 53.32% in 2023. Horizon Databook has segmented the Israel cannabis pharmaceuticals market based on sativex, epidiolex, other brands covering the revenue growth of each sub-segment from 2018 to 2030.
Israel is one of the key markets in the MEA region owing to liberal government policies, technical innovations & high research activity, and a well-developed ecosystem for cannabis.
Furthermore, in 2016, the government announced its plans to expand the number of authorized and trained doctors to prescribe medical cannabis. The Israeli government authorities during 2016, provided licenses to cannabis producers & growers which had a positive impact on the market growth.
Reasons to subscribe to Israel cannabis pharmaceuticals market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Israel cannabis pharmaceuticals market databook
-
Our clientele includes a mix of cannabis pharmaceuticals market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Israel cannabis pharmaceuticals market , including forecasts for subscribers. This country databook contains high-level insights into Israel cannabis pharmaceuticals market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Israel cannabis pharmaceuticals market size, by brand type, 2018-2030 (US$M)
Israel Cannabis Pharmaceuticals Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
